We are pleased to announce the signing of 𝗠𝗲𝗺𝗼𝗿𝗮𝗻𝗱𝘂𝗺 𝗼𝗳 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 (𝗠𝗼𝗨) between 𝗥𝗲𝗺𝗲𝗱𝗶𝘂𝗺𝗢𝗻𝗲 and 𝗡𝗼𝘃𝗮𝘀𝗽𝗶𝗿𝗲 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 on February 13, 2026.

As CROs with complementary strengths, this partnership establishes a stronger foundation to::
1. Expand global reach and sponsor engagement
2. Integrate specialized competencies for streamlined clinical development
3. Enhance efficiency, quality, and innovation across research programs

This reflects a shared commitment to innovation, patient safety, and healthcare development both locally and globally.

We look forward to the initiatives that lie ahead